|Systematic (IUPAC) name|
1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester
|CAS Registry Number|
|Molecular mass||384.47 g/mol|
QUCHIC (BB-22 or 1-(cyclohexylmethyl)-1H-indole-3-carboxylic acid 8-quinolinyl ester) is a designer drug offered by online vendors as a cannabimimetic agent, and was first detected being sold in synthetic cannabis products in Japan in early 2013, and subsequently also in New Zealand. The structure of QUCHIC appears to utilise an understanding of structure-activity relationships within the indole class of cannabimimetics, although its design origins are unclear. QUCHIC, along with QUPIC, represents a structurally unique synthetic cannabinoid chemotype since it contains an ester linker at the indole 3-position rather than the precedented ketone of JWH-018 and its analogues, or the amide of SDB-001 and its analogues. No information regarding the in vitro or in vivo activity of QUCHIC has been published, and only anecdotal reports are known of its pharmacology in humans or other animals.
- Uchiyama, N.; Matsuda, S.; Kawamura, M.; Kikura-Hanajiri, R.; Goda, Y. (2013). "Two new-type cannabimimetic quinolinyl carboxylates, QUPIC and QUCHIC, two new cannabimimetic carboxamide derivatives, ADB-FUBINACA and ADBICA, and five synthetic cannabinoids detected with a thiophene derivative α-PVT and an opioid receptor agonist AH-7921 identified in illegal products". Forensic Toxicology. doi:10.1007/s11419-013-0182-9.
- Dunne bans further two substances found in K2. Press Release: New Zealand Government. Tuesday, 30 April 2013
|This cannabinoid related article is a stub. You can help Wikipedia by expanding it.|